Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Bladder Cancer

Free Subscription Articles published in Urology Retrieve available abstracts of 101 articles: HTML format

Single Articles

December 2025
1. CHOI IW, Ebert KM, Li Q, Finup JL, et al
   A Rare Case of Ewing Sarcoma Presenting in the Adult Bladder-Treatments and Need for More Discussion.
   Urology. 2025;206:90-93.
   PubMed     Abstract available
   
   
   October 2025
2. 
   Expression of Concern: "Letter to the Editor on "Early Adjuvant Chemotherapy Improves Survival in Muscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis"" [Urology, volume 199, 2025, 259-260].
   Urology. 2025;204:370.
   PubMed    
   
   
   
3. REZAEE ME, Mahon KM, Su ZT, Luck KM, et al
   Characterizing Symptoms and Defining Toxicity in Ambulatory Transurethral Resection of Bladder Tumor: Results From a Multicenter Prospective Cohort Study.
   Urology. 2025;204:1-8.
   PubMed     Abstract available
   
   
   
4. LEE MS, Moschini M, Britton CJ, Longoni M, et al
   Development and External Validation of a Local Pelvic Recurrence Risk Score After Radical Cystectomy: Identifying the Ideal Candidate for Adjuvant Radiation Clinical Trials.
   Urology. 2025;204:143-150.
   PubMed     Abstract available
   
   
   September 2025
5. WESTERMAN ME, Delacroix SE Jr
   Editorial Comment: Muscle-Invasive Bladder Cancer Treatment Selection in an Emerging Treatment Era: A Patient Preference Study.
   Urology. 2025 Sep 4:S0090-4295(25)00838-6. doi: 10.1016/j.urology.2025.
   PubMed    
   
   
   August 2025
6. SMITH AB, Gore JL, Chisolm S, Squires P, et al
   Muscle-Invasive Bladder Cancer Treatment Selection in an Emerging Treatment Era: A Patient Preference Study.
   Urology. 2025 Aug 12:S0090-4295(25)00767-8. doi: 10.1016/j.urology.2025.
   PubMed     Abstract available
   
   
   July 2025
7. OBIORA D, Yu M, Sharbaugh D, Bandari J, et al
   Treatment Patterns for Non-Muscle Invasive Bladder Cancer during the Bacillus Calmette-Guerin shortage.
   Urology. 2025 Jul 23:S0090-4295(25)00711-3. doi: 10.1016/j.urology.2025.
   PubMed     Abstract available
   
   
   June 2025
8. MACINTYRE I, Kool R, Marcq G, Kulkarni GS, et al
   Effect of Sex Differences on Cancer Outcomes after Chemo-Radiation for Muscle-Invasive Bladder Cancer: A Retrospective Multicenter Cohort Study.
   Urology. 2025 Jun 28:S0090-4295(25)00636-3. doi: 10.1016/j.urology.2025.
   PubMed     Abstract available
   
   
   
9. THAKUR A, Kumar L
   Reply to editor comment on "A Comparison Between Intravesical Gemcitabine Plus Docetaxel and Intravesical Bacillus Calmette-Guerin in the Treatment of Nonmuscle Invasive Naive Urinary Bladder Cancer: A Systematic Review and Meta-analysis of Oncologica
   Urology. 2025 Jun 16:S0090-4295(25)00600-4. doi: 10.1016/j.urology.2025.
   PubMed    
   
   
   
10. STARR S, Kazemi S, Moman P, Lin L, et al
    Disparities in Access to High Volume Centers for Muscle Invasive Bladder Cancer and its Association With Treatment Patterns and Outcomes.
    Urology. 2025 Jun 12:S0090-4295(25)00595-3. doi: 10.1016/j.urology.2025.
    PubMed     Abstract available
    
    
    
11. BELAND LE, Van Batavia JP, Mittal S, Kolon TF, et al
    Inflammatory Myofibroblastic Tumor of the Bladder in Childhood: A Three Case Series.
    Urology. 2025;200:e72-e75.
    PubMed     Abstract available
    
    
    May 2025
12. WANG J, Ma R, Wu X, Yang W, et al
    Letter to the Editor on "A Comparison Between Intravesical Gemcitabine Plus Docetaxel and Intravesical Bacillus Calmette-Guerin in the Treatment of Nonmuscle Invasive Naive Urinary Bladder Cancer: A Systematic Review and Meta-analysis of Oncological O
    Urology. 2025 May 29:S0090-4295(25)00513-8. doi: 10.1016/j.urology.2025.
    PubMed    
    
    
    
13. HIGGINS MI, Li J, Ahmed W, Lu C, et al
    Detection Of High-Grade Bladder Cancer In Urine Samples Using In Situ Hybridization Of Long Non-Coding RNA UCA1.
    Urology. 2025 May 13:S0090-4295(25)00468-6. doi: 10.1016/j.urology.2025.
    PubMed     Abstract available
    
    
    April 2025
14. ACOSTA AM, Saad M, Chaux A, Gordetsky JB, et al
    Differential Outcomes in Bladder Cancer After Neoadjuvant Chemotherapy: An International Multi-Institutional Study Comparing Isolated Nodal Disease versus Persistent Muscle-Invasive Disease.
    Urology. 2025 Apr 16:S0090-4295(25)00345-0. doi: 10.1016/j.urology.2025.
    PubMed     Abstract available
    
    
    
15. LONGONI M, Penaranda NR, Marmiroli A, Falkenbach F, et al
    Reply to Editorial Comment on "Survival Outcomes And Temporal Trends Of Non-Surgical Management Versus Radical Cystectomy In Non-Organ-Confined Urothelial Bladder Cancer".
    Urology. 2025 Apr 15:S0090-4295(25)00341-3. doi: 10.1016/j.urology.2025.
    PubMed    
    
    
    
16. JOYCE DD
    Editorial Comment on "Real-World Economic Burden and Healthcare Resource Utilization of Radical Cystectomy and Trimodal Therapy for Bladder Cancer in the United States".
    Urology. 2025 Apr 7:S0090-4295(25)00317-6. doi: 10.1016/j.urology.2025.
    PubMed    
    
    
    
17. SAITO K, Nakayama A
    Editorial comments on Survival outcomes and temporal trends of non-surgical management versus radical cystectomy in non-organ-confined urothelial bladder cancer.
    Urology. 2025 Apr 4:S0090-4295(25)00319-X. doi: 10.1016/j.urology.2025.
    PubMed    
    
    
    March 2025
18. WILLIAMS SB, Yapici HO, Singhal PK, Weimer I, et al
    Real-World Economic Burden and Healthcare Resource Utilization of Radical Cystectomy and Trimodal Therapy for Bladder Cancer in the United States.
    Urology. 2025 Mar 21:S0090-4295(25)00280-8. doi: 10.1016/j.urology.2025.
    PubMed     Abstract available
    
    
    
19. MALSHY K, Bandari J, Cheng Z, Kadambi S, et al
    Tailoring Cystoscopy Surveillance: Addressing the Needs of Frail Bladder Cancer Patients.
    Urology. 2025 Mar 21:S0090-4295(25)00253-5. doi: 10.1016/j.urology.2025.
    PubMed    
    
    
    
20. SADE JP, Ferraris F, Raman J
    The (Re) evolution in the treatment of bladder cancer.
    Urology. 2025 Mar 21:S0090-4295(25)00287-0. doi: 10.1016/j.urology.2025.
    PubMed    
    
    
    
21. LONGONI M, Penaranda NR, Marmiroli A, Falkenbach F, et al
    Survival outcomes and temporal trends of non-surgical management versus radical cystectomy in non-organ-confined urothelial bladder cancer.
    Urology. 2025 Mar 6:S0090-4295(25)00216-X. doi: 10.1016/j.urology.2025.
    PubMed     Abstract available
    
    
    
22. CETIN T, Bolat D, Akgul M, Yazici S, et al
    Effect of Bacillus Calmette-Guerin Instillation Timing on Oncological Survivals After Transurethral Resection of Bladder Tumor.
    Urology. 2025;197:126-132.
    PubMed     Abstract available
    
    
    February 2025
23. TRIPATHY R, Kumar L
    Editorial Comment on "A comparison between intravesical Gemcitabine plus Docetaxel and intravesical BCG in the treatment of non-muscle invasive naive urinary bladder cancer: A systematic review and meta-analysis of oncological outcomes".
    Urology. 2025 Feb 19:S0090-4295(25)00176-1. doi: 10.1016/j.urology.2025.
    PubMed    
    
    
    
24. MICHAEL PD, Campbell RA
    Editorial comment on "A comparison between intravesical Gemcitabine plus Docetaxel and intravesical BCG in the treatment of non-muscle invasive naive urinary bladder cancer: A systematic review and meta-analysis of oncological outcomes".
    Urology. 2025 Feb 10:S0090-4295(25)00139-6. doi: 10.1016/j.urology.2025.
    PubMed    
    
    
    January 2025
25. KUMAR S, Razaqi N, Mehta R, Sah R, et al
    Comment on "Early Adjuvant Chemotherapy Improves Survival in Muscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis".
    Urology. 2025 Jan 29:S0090-4295(25)00008-1. doi: 10.1016/j.urology.2025.
    PubMed    
    
    
    
26. TRIPATHY R, Kumar L, Agarwal S, Thakur A, et al
    A comparison between intravesical gemcitabine plus docetaxel and intravesical BCG in the treatment of non-muscle invasive naive urinary bladder cancer: A systematic review and meta-analysis of oncological outcomes.
    Urology. 2025 Jan 9:S0090-4295(25)00006-8. doi: 10.1016/j.urology.2025.
    PubMed     Abstract available
    
    
    December 2024
27. ECKE TH, Meisl CJ, Schlomm T, Rabien A, et al
    Performance of urinary markers in patients with suspicious cystoscopy during follow-up of recurrent non-muscle invasive bladder cancer: BTA stat(R), NMP22(R) BladderChek(R), UBC(R) Rapid Test, CancerCheck(R) UBC(R) rapid VISUAL, and uromonitor(R) in c
    Urology. 2024 Dec 1:S0090-4295(24)01113-0. doi: 10.1016/j.urology.2024.
    PubMed     Abstract available
    
    
    
28. ZENG E, Saucke M, Pati B, Rose A, et al
    "...I Wish Someone Told Me About That...": A Qualitative Assessment of the Educational Needs of Patients Undergoing Cystectomy.
    Urology. 2024;194:348-355.
    PubMed     Abstract available
    
    
    
29. MEKAYTEN M, Tin AL, Sidhu A, Liso N, et al
    Trans Oblique Ileal Conduit Technique Has a Low Risk of Parastomal Hernias.
    Urology. 2024;194:241-246.
    PubMed     Abstract available
    
    
    November 2024
30. YEGUEZ AC, Talwar R, Smith AL
    Optimizing Care for Women through Gynecologic Organ Considerations During Cystectomy: A Pre-Operative Checklist of Important Considerations.
    Urology. 2024 Nov 28:S0090-4295(24)01095-1. doi: 10.1016/j.urology.2024.
    PubMed     Abstract available
    
    
    
31. LIU H, Jin L, Shi J
    Incidence and risk factors for postoperative acute kidney injury after radical cystectomy for bladder cancer.
    Urology. 2024 Nov 25:S0090-4295(24)01092-6. doi: 10.1016/j.urology.2024.
    PubMed    
    
    
    
32. SANKIN A, Dave P, Cherrill LR, Boucher RH, et al
    Low-grade Urothelial Carcinoma Recurs at a Tempo that Naturally Accelerates Over Time.
    Urology. 2024;193:166-172.
    PubMed     Abstract available
    
    
    
33. SANCHEZ B C, Rickard M, Denburg A, Khondker A, et al
    Bladder Embryonal Rhabdomyosarcoma Presenting in the Perinatal Period: Report of Two Consecutive Cases.
    Urology. 2024;193:e85-e88.
    PubMed     Abstract available
    
    
    
34. ABOU HEIDAR N, Mahmood AW, Khan M, Harrington G, et al
    Does Ta Low-grade Urothelial Carcinoma of the Bladder With Focal High-grade Features Carry Worse Prognosis? The Roswell Park Comprehensive Cancer Center Experience.
    Urology. 2024;193:136-142.
    PubMed     Abstract available
    
    
    October 2024
35. OZDEMIR MS, Keskin ET, Savun M, Yuzkan S, et al
    VI-RADS-Based Algorithm for Bladder Cancer Management Randomized Retrospective Study.
    Urology. 2024 Oct 17:S0090-4295(24)00867-7. doi: 10.1016/j.urology.2024.
    PubMed     Abstract available
    
    
    
36. AIZPURUA XP, Gardiner JIM, Popescu OB, Gonzalez EB, et al
    A Systematic Review on the Current Landscape of T1 Bladder Cancer Substaging.
    Urology. 2024 Oct 8:S0090-4295(24)00880-X. doi: 10.1016/j.urology.2024.
    PubMed     Abstract available
    
    
    September 2024
37. FU H, Anele UA, Messer JC
    Editorial Commentary on: "Exposures and Bladder Cancer Risk Among Military Veterans: A Systematic Review and Meta-analysis".
    Urology. 2024 Sep 10:S0090-4295(24)00793-3. doi: 10.1016/j.urology.2024.
    PubMed    
    
    
    
38. KRONSTEDT S, Saffati G, Hinojosa-Gonzalez DE, Doppalapudi SK, et al
    Early Adjuvant Chemotherapy Improves Survival in Muscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis.
    Urology. 2024 Sep 2:S0090-4295(24)00770-2. doi: 10.1016/j.urology.2024.
    PubMed     Abstract available
    
    
    
39. DALL CP, Liu X, Faraj KS, Srivastava A, et al
    Teaching Hospitals and Textbook Outcomes After Major Urologic Cancer Surgery.
    Urology. 2024;191:64-70.
    PubMed     Abstract available
    
    
    August 2024
40. KRONSTEDT S, Cathey J, Chiu CB, Saffati G, et al
    Exposures and Bladder Cancer Risk Among Military Veterans: A Systematic Review and Meta-analysis.
    Urology. 2024 Aug 15:S0090-4295(24)00659-9. doi: 10.1016/j.urology.2024.
    PubMed     Abstract available
    
    
    
41. TABER C, Lee B, Djang R, Shone E, et al
    Evaluating the Differences of Wound Related Complications in Robotically Assisted Radical Cystectomy vs Open Radical Cystectomy.
    Urology. 2024;190:56-62.
    PubMed     Abstract available
    
    
    
42. RICH JM, Sfakianos JP
    Reply to Editorial Comment on "Thromboembolic Events After Robotic Radical Cystectomy: A Comparative Analysis of Extended and Limited Prophylaxis".
    Urology. 2024;190:54-55.
    PubMed    
    
    
    
43. COWAN AN, Rosen GH
    Editorial Comment on "Thromboembolic Events After Robotic Radical Cystectomy: A Comparative Analysis of Extended and Limited Prophylaxis".
    Urology. 2024;190:53.
    PubMed    
    
    
    
44. RICH JM, Geduldig J, Elkun Y, Lavallee E, et al
    Thromboembolic Events After Robotic Radical Cystectomy: A Comparative Analysis of Extended and Limited Prophylaxis.
    Urology. 2024;190:46-52.
    PubMed     Abstract available
    
    
    July 2024
45. RICHARDS KA
    Editorial comment on "Sequential intravesical chemotherapy for treatment naive, high-risk non-muscle invasive bladder cancer: oncologic outcomes, tolerance, and comparison to contemporary controls.
    Urology. 2024 Jul 21:S0090-4295(24)00591-0. doi: 10.1016/j.urology.2024.
    PubMed    
    
    
    June 2024
46. CABRAL JD, Modi PK
    Editorial Comment on "Social Vulnerability and Receipt of Neoadjuvant Chemotherapy in Patients Undergoing Radical Cystectomy for Bladder Cancer".
    Urology. 2024 Jun 20:S0090-4295(24)00469-2. doi: 10.1016/j.urology.2024.
    PubMed    
    
    
    
47. LIU WJ, Campbell RA, Michael PD, Wood A, et al
    Clinical upstaging after neoadjuvant chemotherapy impacting eligibility for vaginal-sparing cystectomy: identifying bladder cancer patients who may benefit from interim imaging.
    Urology. 2024 Jun 20:S0090-4295(24)00474-6. doi: 10.1016/j.urology.2024.
    PubMed     Abstract available
    
    
    
48. REFUGIA JM, Roebuck E, Thakker P, Sandberg M, et al
    Sequential Intravesical Chemotherapy for Treatment Naive, High-Risk Non-Muscle Invasive Bladder Cancer: Oncologic Outcomes, Tolerance, and Comparison to Contemporary Controls.
    Urology. 2024 Jun 19:S0090-4295(24)00463-1. doi: 10.1016/j.urology.2024.
    PubMed     Abstract available
    
    
    
49. CONNORS C, Wang D, Levy M, Ravivarapu KT, et al
    Transurethral Resection of Bladder Tumor Outcomes Are Predicted by a 5-Item Frailty Index.
    Urology. 2024;188:104-110.
    PubMed     Abstract available
    
    
    May 2024
50. SEKAR RR, Irani S, Maganty A, Montgomery JS, et al
    Social Vulnerability and Receipt of Neoadjuvant Chemotherapy in Patients Undergoing Radical Cystectomy for Bladder Cancer.
    Urology. 2024 May 17:S0090-4295(24)00359-5. doi: 10.1016/j.urology.2024.
    PubMed     Abstract available
    
    
    
51. YU J, Wang CG, Zhang Y, Yang W, et al
    A Novel Approach to Treatment with Antiangiogenic Agents in Adenocarcinoma of Urachal Origin.
    Urology. 2024;187:121-122.
    PubMed    
    
    
    
52. BRANDT SB, Kingo PS, Laurberg JR, Lam GW, et al
    Reply to Editorial comments on "Definition of Benign Ureteroenteric Anastomotic Strictures in Ileal Conduits After Radical Cystectomy: Experience From a Single Center and Previously Published Literature".
    Urology. 2024;187:139.
    PubMed    
    
    
    
53. BRANDT SB, Kingo PS, Laurberg JR, Lam GW, et al
    Definition of Benign Ureteroenteric Anastomotic Strictures in Ileal Conduits After Radical Cystectomy: Experience From a Single Center and Previously Published Literature.
    Urology. 2024;187:131-136.
    PubMed     Abstract available
    
    
    
54. LIN JS, Zhao LC
    Editorial comments on "Definition of Benign Ureteroenteric Anastomotic Strictures in Ileal Conduits After Radical Cystectomy: Experience From a Single Center and Previously Published Literature".
    Urology. 2024;187:137-138.
    PubMed    
    
    
    
55. MORAN M, Kim JE, Fu MZ, Ghodoussipour S, et al
    Worsening Neobladder Incontinence in a Patient on Nivolumab Therapy.
    Urology. 2024;187:92-93.
    PubMed    
    
    
    April 2024
56. EULE CJ, Warren A, Kuna EM, Callihan EB, et al
    Neoadjuvant cisplatin-based chemotherapy in nonmetastatic muscle-invasive bladder cancer: A systematic review and pooled meta-analysis to determine the preferred regimen.
    Urology. 2024 Apr 27:S0090-4295(24)00306-6. doi: 10.1016/j.urology.2024.
    PubMed     Abstract available
    
    
    
57. HARDESTY JK, Burns RT, Soyster ME, Jansen NE, et al
    Female Bladder Dysfunction Following Boari Bladder Flap Ureteral Reconstruction.
    Urology. 2024;186:31-35.
    PubMed     Abstract available
    
    
    March 2024
58. HUELSTER HL, Mason NT, Davaro F, Naqvi SMH, et al
    Cost-Utility of Initial Management of High-grade T1 Bladder Cancer with Intravesical BCG vs Immediate Radical Cystectomy.
    Urology. 2024 Mar 9:S0090-4295(24)00126-2. doi: 10.1016/j.urology.2024.
    PubMed     Abstract available
    
    
    
59. SAHNI DS, Oberoi AS, Ramsaha S, Teahan S, et al
    Incidence of Ureteroenteric Anastomotic Strictures After Robotic vs Open Cystectomy in Adults.
    Urology. 2024;185:100-108.
    PubMed     Abstract available
    
    
    February 2024
60. LIBLIK K, Queen JC, Touma NJ
    Immune Checkpoint Inhibitors for Kidney and Bladder Cancer: Adrenotoxic Consequences.
    Urology. 2024 Feb 29:S0090-4295(24)00129-8. doi: 10.1016/j.urology.2024.
    PubMed    
    
    
    
61. CARLTON CE, Christie AL, Prokesch BC, Chao TC, et al
    Robotic simple cystectomy as a last resort for antibiotic-recalcitrant recurrent urinary tract infections in women.
    Urology. 2024 Feb 21:S0090-4295(24)00108-0. doi: 10.1016/j.urology.2024.
    PubMed     Abstract available
    
    
    
62. LEPOR H, Wiegand L, Patel K, Du W, et al
    A Randomized Clinical Trial Evaluating Indigo Carmine as a Visualization Aid for Evaluating Ureteral Patency.
    Urology. 2024;184:105-111.
    PubMed     Abstract available
    
    
    
63. WEISS K, Abimbola O, Miller K, Kim WY, et al
    Near Complete Response to Platinum-based Systemic Chemotherapy in High-risk Upper Tract Urothelial Carcinoma With an ERBB2 Gene Mutation: A Case Report.
    Urology. 2024;184:75-78.
    PubMed     Abstract available
    
    
    January 2024
64. MORRIS KE, Pappas TN
    Malignancy in the public life: the story of Hubert Humphrey's bladder cancer.
    Urology. 2024 Jan 31:S0090-4295(24)00017-7. doi: 10.1016/j.urology.2023.
    PubMed    
    
    
    
65. PETEINARIS A, Gkeka K, Katsakiori P, Tatanis V, et al
    Replicating Florence Intracorporeal Neobladder Technique in Laparoscopic Radical Cystectomy: A Retrospective Study.
    Urology. 2024;183:106-110.
    PubMed     Abstract available
    
    
    
66. KIM AH, Ruel NH, Yamzon J, Zhumkhawala AA, et al
    Indiana Pouch Continent Cutaneous Urinary Diversion After Robotic-assisted Radical Cystectomy: A 16-Year Experience.
    Urology. 2024;183:e325-e327.
    PubMed     Abstract available
    
    
    December 2023
67. RICHARDS HL, Fortune DG, Lyons L, Curtin Y, et al
    Patients' emotional talk during surveillance cystoscopy for non-muscle invasive bladder cancer - opportunities for improving communication.
    Urology. 2023 Dec 29:S0090-4295(23)01116-0. doi: 10.1016/j.urology.2023.
    PubMed     Abstract available
    
    
    
68. ZHU A, Srivastava A
    Editorial Comment: Does Alexis Wound Protector/Retractor Reduce the Risk of Surgical Site Infections After Open Radical Cystectomy for Bladder Cancer? Results From a Single Center, Comparative Study.
    Urology. 2023 Dec 14:S0090-4295(23)00958-5. doi: 10.1016/j.urology.2023.
    PubMed    
    
    
    
69. GUL ZG, Wu S, Raver M, Vasan R, et al
    A Multipronged Intervention to Reduce Readmissions and Readmission Intensity After Radical Cystectomy.
    Urology. 2023;182:155-160.
    PubMed     Abstract available
    
    
    November 2023
70. GALOSI AB, Fave RFD, Perpepaj L, Milanese G, et al
    Does Alexis(c) wound protector/retractor reduce the risk of surgical site infections after open radical cystectomy for bladder cancer? Results from a single center, comparative study.
    Urology. 2023 Nov 6:S0090-4295(23)00951-2. doi: 10.1016/j.urology.2023.
    PubMed     Abstract available
    
    
    
71. ARCEO-OLAIZ R, Smith EA, Stokes C, Eaton BR, et al
    Use of Perirectal Hyaluronic Acid Spacer Prior to Radiotherapy in a Pediatric Patient With Bladder Rhabdomyosarcoma: A Case Report.
    Urology. 2023;181:136-140.
    PubMed     Abstract available
    
    
    
72. TUA-CARACCIA R, Livingston A, Routh JC
    Recurrent Papillary Bladder Tumors in a Boy With Lynch Syndrome.
    Urology. 2023;181:133-135.
    PubMed     Abstract available
    
    
    October 2023
73. HYLLESTED E, Vejlgaard M, Stroomberg HV, Maibom SL, et al
    Reply by Authors: Acute Kidney Injury Within 90Days of Radical Cystectomy for Bladder Cancer: Incidence and Risk Factors.
    Urology. 2023 Oct 21:S0090-4295(23)00810-5. doi: 10.1016/j.urology.2023.
    PubMed    
    
    
    
74. GRECO F, Domanico L, Lembo F
    Editorial Comment to Acute Kidney Injury Within 90Days of Radical Cystectomy for Bladder Cancer: Incidence and Risk Factors.
    Urology. 2023 Oct 21:S0090-4295(23)00809-9. doi: 10.1016/j.urology.2023.
    PubMed    
    
    
    September 2023
75. HYLLESTED E, Vejlgaard M, Stroomberg HV, Maibom SL, et al
    Acute Kidney Injury within 90 days of Radical Cystectomy for Bladder Cancer: Incidence and Risk Factors.
    Urology. 2023 Sep 22:S0090-4295(23)00807-5. doi: 10.1016/j.urology.2023.
    PubMed     Abstract available
    
    
    
76. VEJLGAARD M, Maibom SL, Joensen UN, Moser C, et al
    Microbial trends in infection-related readmissions following radical cystectomy for bladder cancer.
    Urology. 2023 Sep 22:S0090-4295(23)00805-1. doi: 10.1016/j.urology.2023.
    PubMed     Abstract available
    
    
    
77. PENN T, Borza T, Liou JI, Jason Abel E, et al
    The Impact of Agent Orange Exposure on Non-Muscle Invasive Bladder Cancer Outcomes.
    Urology. 2023 Sep 18:S0090-4295(23)00794-X. doi: 10.1016/j.urology.2023.
    PubMed     Abstract available
    
    
    
78. NABAVIZADEH R, Pessoa RR, Dumbrava MG, Packiam VT, et al
    Cutaneous Ureterostomy Following Radical Cystectomy for Bladder Cancer: A Contemporary Series.
    Urology. 2023 Sep 7:S0090-4295(23)00733-1. doi: 10.1016/j.urology.2023.
    PubMed     Abstract available
    
    
    
79. LYALL V, Aziz Ould Ismail A, Haggstrom DA, Issa MM, et al
    Accurate Documentation Contributes to Guideline-concordant Surveillance of Non-Muscle Invasive Bladder Cancer: a Multi-site VA Study.
    Urology. 2023 Sep 1:S0090-4295(23)00729-X. doi: 10.1016/j.urology.2023.
    PubMed     Abstract available
    
    
    
80. MAJDALANY SE, Yaguchi G, Arora S, Ray C, et al
    Genital Sparing Robot-Assisted Radical Cystectomy with Intracorporeal Neobladder & Paravaginal Repair.
    Urology. 2023;179:202-203.
    PubMed     Abstract available
    
    
    August 2023
81. RANTI D, Dey L, Bieber C, Grauer R, et al
    Surveillance for Non-Muscle Invasive Bladder Cancer: Identifying the point of Diminishing Returns.
    Urology. 2023 Aug 19:S0090-4295(23)00697-0. doi: 10.1016/j.urology.2023.
    PubMed     Abstract available
    
    
    
82. HYMAN MJ, Skolarus TA, Litwack K, Meltzer DO, et al
    Outcomes of Hematuria Evaluation by Advanced Practice Providers and Urologists.
    Urology. 2023;178:67-75.
    PubMed     Abstract available
    
    
    July 2023
83. PASTER IC, Chipollini J
    Reply: Gender, Racial and Ethnic Differences in Pathologic Response Following Neoadjuvant Chemotherapy for Bladder Cancer Patients.
    Urology. 2023 Jul 11:S0090-4295(23)00448-X. doi: 10.1016/j.urology.2023.
    PubMed    
    
    
    
84. SEKAR RR, Maganty A
    Impact of Race, Ethnicity, and Gender on Response to Neoadjuvant Chemotherapy and Survival in Patients With Muscle-invasive Bladder Cancer.
    Urology. 2023 Jul 11:S0090-4295(23)00447-8. doi: 10.1016/j.urology.2023.
    PubMed    
    
    
    
85. JEVNIKAR B, Slopnick E, Almassi N
    Clinical Challenge in Urology: Late Genitourinary Toxicity Following Intravesical Bacillus Calmette-Guerin.
    Urology. 2023;177:e8-e9.
    PubMed    
    
    
    
86. GELDMAKER LE, Baird BA, Hasse CH, Haehn DA, et al
    Analysis of Transurethral Resection of Bladder Tumor Efficiency Utilizing Nonprocedural Operating Room Times.
    Urology. 2023;177:6-11.
    PubMed     Abstract available
    
    
    
87. KANABOLO DL, Park S
    Prophylactic Mesh Placement With Ileal Conduit: A Cost-effectiveness Analysis.
    Urology. 2023;177:197-203.
    PubMed     Abstract available
    
    
    
88. FENG S, Yang Y, Yu Z, Xiong Q, et al
    Survival and Analysis of Prognostic Factors for Bladder Malignancies in Children and Adolescents: A Population-based Study.
    Urology. 2023;177:156-161.
    PubMed     Abstract available
    
    
    
89. SOYSTER ME, Arnold PJ, Burns RT, Zappia JL, et al
    Ileal Ureter Utilization in Patients With Previous Urinary Diversions.
    Urology. 2023;177:184-188.
    PubMed     Abstract available
    
    
    June 2023
90. TAN WP
    An Atypical Bladder Mass: Extra Adrenal Paraganglioma.
    Urology. 2023;176:e8-e9.
    PubMed    
    
    
    
91. ERGUN O, Alperen Ozturk S, Kircicek F, Gurdal O, et al
    Increased Plasma Ignition Distance Practice may Prevent the Obturator Reflex Occurrences and Compare of its Effectiveness Versus Obturator Block: A Prospective, Randomized, Controlled Study.
    Urology. 2023;176:226-231.
    PubMed     Abstract available
    
    
    May 2023
92. PASTER IC, Zeng J, Recio-Boiles A, Chipollini J, et al
    Gender, racial and ethnic differences in pathologic response following neoadjuvant chemotherapy for bladder cancer patients.
    Urology. 2023 May 23:S0090-4295(23)00446-6. doi: 10.1016/j.urology.2023.
    PubMed     Abstract available
    
    
    
93. WAHLEN MM, McElree IM, Packiam VT
    Editorial Comment On: Variation in Statewide Intravesical Treatment Rates for Non-Muscle Invasive Bladder Cancer During the BCG Drug Shortage.
    Urology. 2023 May 19:S0090-4295(23)00371-0. doi: 10.1016/j.urology.2023.
    PubMed    
    
    
    
94. GROOTEMAAT M, Tjiam I, Sampimon D, Bot F, et al
    Bilateral Adrenal and testicular Tumours; When a Simple Diagnosis Becomes Complicated.
    Urology. 2023;175:e11-e12.
    PubMed     Abstract available
    
    
    April 2023
95. MILLER DT, Sun Z, Grajales V, Pekala KR, et al
    Insurance type and area deprivation are associated with worse overall mortality for patients with muscle-invasive bladder cancer.
    Urology. 2023 Apr 5:S0090-4295(23)00270-4. doi: 10.1016/j.urology.2023.
    PubMed     Abstract available
    
    
    
96. ZHANG JH, Starr SL, Chamie K
    Contemporary Systemic Therapies in Urothelial Carcinoma.
    Urology. 2023;174:150-158.
    PubMed     Abstract available
    
    
    
97. JUE JS, Armenakas NA
    Upper Tract Tumor En Bloc Enucleation: A Novel Approach to the Diagnosis and Management of Upper Tract Urothelial Carcinoma.
    Urology. 2023;174:196-200.
    PubMed     Abstract available
    
    
    
98. SONG SH, Kim JH, Lee S, Hong SK, et al
    Total Intracorporeal Versus Open Bladder Cuffing in Robotic Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma.
    Urology. 2023;174:111-117.
    PubMed     Abstract available
    
    
    March 2023
99. CHUN B, He M, Jones C, Vasan R, et al
    Variation in Statewide Intravesical Treatment Rates for Non-Muscle Invasive Bladder Cancer During the BCG Drug Shortage.
    Urology. 2023 Mar 25:S0090-4295(23)00267-4. doi: 10.1016/j.urology.2023.
    PubMed     Abstract available
    
    
    
100. DONAT SM, Sonoda Y, Al-Ahmadie H, Murali R, et al
     Evaluation of Women With a Positive Urine Cytology and no Demonstrable Disease in the Urinary Tract.
     Urology. 2023;173:10-16.
     PubMed     Abstract available
     
     
     
101. RAM P, Mandal S, Das MK, Nayak P, et al
     Association of Increased Age With Decreased Response to Intravesical Instillation of Bacille Calmette-Guerin in Patients With High-Risk Non-Muscle Invasive Bladder Cancer: Retrospective Multi-Institute Results From the Japanese Urological Oncology Res
     Urology. 2023;173:229.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.